Clinical Trials

A randomized, double-blind, placebo-controlled, multicenter, phase 3 efficacy and safety study of subcutaneous anakinra (Kineret®) in patients with Still’s disease (SJIA and AOSD) followed by an open-label extension


Research Study Number:
Pro2017-0475

Short Title:
Sobi. ANAKIN-301

Division:
Rheumatology

Study Status:
Enrolling